A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
Clinical trial NCT03496974 · COMPLETED
Trial details
- NCT number
- NCT03496974
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-21
- Primary completion
- 2018-12-04
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.